loading

Why is Brainstorm Cell Therapeutics, Inc. (BCLI) Stock down?

We've noticed a 8.74% decline in Brainstorm Cell Therapeutics, Inc. (BCLI) stock during the 2024-05-14 trading session. While this could be attributed to normal volatility or various internal and external factors, please be aware that we are actively monitoring the situation, and we'll provide timely updates as soon as possible!
28 Sep, 2023:

Shares of Brainstorm Cell Therapeutics Inc. (BCLI) were down 47.73% to $0.20 after the company announced the FDA Advisory Committee voted that NurOwn did not demonstrate substantial evidence of effectiveness for treatment of mild to moderate ALS.

https://www.benzinga.com/news/earnings/23/09/34981141/crude-oil-moves-lower-carmax-posts-downbeat-earnings

25 Sep, 2023:

Brainstorm Cell Therapeutics Inc. (BCLI) fell 47.57% to $0.4277 after the FDA said it does not believe there is sufficient evidence to support that any of the assessed biomarkers for the company's ALS therapy is reasonably likely to predict clinical benefit.

https://www.benzinga.com/news/23/09/34873722/why-brainstorm-cell-therapeutics-shares-are-trading-lower-by-33-here-are-other-stocks-moving-in-mond

$77.18
price down icon 0.12%
$168.84
price up icon 0.90%
$151.07
price up icon 1.04%
$29.84
price up icon 2.31%
$368.65
price up icon 3.46%
$92.00
price down icon 0.11%
Cap:     |  Volume (24h):